| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
83,754,000 |
| Market
Cap: |
1.65(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.58 - $23.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
50,000 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$575,000 |
$575,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
17,850 |
108,902 |
108,902 |
125,502 |
| Total Sell Value |
$335,832 |
$2,177,814 |
$2,177,814 |
$2,411,082 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
6 |
6 |
11 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dale Stephen |
Chief Medical Officer |
• – – |
2024-01-30 |
4 |
AS |
$21.55 |
$103,980 |
D/D |
(4,825) |
38,817 |
|
-6% |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2024-01-29 |
4 |
AS |
$17.80 |
$127,416 |
D/D |
(7,158) |
43,642 |
|
6% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2024-01-29 |
4 |
S |
$17.80 |
$26,630 |
D/D |
(1,496) |
21,602 |
|
-2% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2024-01-29 |
4 |
S |
$17.80 |
$36,544 |
D/D |
(2,053) |
68,979 |
|
-2% |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2024-01-29 |
4 |
S |
$17.80 |
$41,262 |
D/D |
(2,318) |
48,093 |
|
-2% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2024-01-24 |
4 |
AS |
$20.23 |
$1,841,982 |
D/D |
(91,052) |
559 |
|
0% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2024-01-24 |
4 |
OE |
$4.80 |
$550,594 |
D/D |
91,052 |
84,666 |
|
- |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
46,250 |
71,032 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
21,250 |
50,411 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2023-12-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
279,194 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2023-12-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
559 |
|
- |
|
| Malley Thomas |
Director |
– • – |
2023-06-16 |
4 |
B |
$11.50 |
$575,000 |
I/I |
50,000 |
139,557 |
2.1 |
-29% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2023-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,966) |
2,559 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2023-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
308,394 |
300,000 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2023-06-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(862,212) |
280,194 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,625 |
27,466 |
|
- |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
23,125 |
50,800 |
|
- |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
23,125 |
23,125 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2023-01-27 |
4 |
S |
$13.89 |
$21,502 |
D/D |
(1,548) |
16,841 |
|
-2% |
|
| Dale Stephen |
Chief Medical Officer |
• – – |
2023-01-27 |
4 |
AS |
$13.87 |
$128,033 |
D/D |
(9,225) |
27,675 |
|
2% |
|
| Flowers Kirsten |
CCO & Chief Strategy Officer |
• – – |
2023-01-27 |
4 |
S |
$13.89 |
$26,474 |
D/D |
(1,906) |
20,605 |
|
-2% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2023-01-27 |
4 |
S |
$13.89 |
$25,294 |
D/D |
(1,821) |
21,214 |
|
-2% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2022-11-17 |
4 |
AS |
$15.22 |
$31,965 |
D/D |
(2,100) |
0 |
|
-19% |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2022-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,084,300 |
1,125,618 |
|
- |
|
115 Records found
|
|
Page 1 of 5 |
|
|
0.65 (3.42%) 
